FDA Commissioner Scott Gottlieb, MD, will be stepping down from his post in 1 month.
FDA Commissioner Scott Gottlieb, MD, will be stepping down from his post in 1 month. Since taking office, he has encouraged generic drug competition and the growth of biosimilars in the US healthcare system.
In a note to the FDA, Gottlieb explained that he was stepping down because of the time he has spent away from his wife and 3 young children.
"I know that the opportunity to serve in this role was a privelege, and an endeavor that I'll never be able to replicate in my professional life—the impact of our public health work, the camaraderie, and our ability to improve the lives of Americans," he wrote. "There are many important efforts we undertook together, countless new policies we advanced, and laws we enforced with vigor to protect consumers."
He added that in his final weeks as commissioner, he will continue to cement the work he started and secure the 2020 budget.
“All of us at HHS are proud of the remarkable work Commissioner Gottlieb has done at the FDA,” HHS Secretary Alex Azar said in a statement. “He has been an exemplary public health leader, aggressive advocate for American patients, and passionate promoter of innovation. I will personally miss working with Scott on the important goals we share, and I know that is true for so many other members of the HHS family.”
President Donald Trump sent out a tweet thanking Gottlieb for his work:
Scott Gottlieb, who has done an absolutely terrific job as Commissioner of the FDA, plans to leave government service sometime next month....
— Donald J. Trump (@realDonaldTrump) March 5, 2019
Under Gottlieb, the FDA released in 2018 the Biosimilar Action Plan, which was meant to spur biosimilar competition. The plan addressed 4 key areas in order to spur biosimilar competition:
In January 2019, Gottlieb outlined his goals for the year at the JP Morgan Healthcare Conference. These goals included bringing down drug prices through increased competition and a robust biosimilars market.
When Gottlieb was nominated to become FDA commissioner, he was met with scrutiny over his industry ties and his opposition to many regulations. Ultimately, he was confirmed mostly along party lines in a 57 to 42 vote.
"Scott’s leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use, chronic disease, and more,” Azar said. “The public health of our country is better off for the work Scott and the entire FDA team have done over the last 2 years.”
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.